PR Newswire07.14.20
Sight Sciences Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, has launched its next-generation OMNI Surgical System for microinvasive glaucoma surgery (MIGS) procedures.
The OMNI Surgical System combines two distinct angle procedures, ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS device that allows surgeons to target all three points of aqueous humor outflow resistance: trabecular meshwork, Schlemm's canal and distal collector channels.
"We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery," said Sight Sciences Chief Commercial Officer Shawn O'Neil. "We're excited to announce the availability of this improved system, which incorporates many changes based on feedback from our physician customers."
The upgraded system features several updates designed to enhance its ergonomics and usability including:
"The OMNI Surgical System has been revolutionary for my practice because of its effectiveness and ability to offer titratable therapy to a wide range of patients with glaucoma," said Blake K. Williamson M.D., MPH, MS, refractive surgeon and MIGS expert at Williamson Eye in Baton Rouge, La. "These changes will improve the functionality and intuitive use of the OMNI System, making it even more comfortable and efficient to perform both viscodilations and trabeculotomies."
Initial published results from early use of the OMNI Surgical System show meaningful reductions in intraocular pressure (IOP) and medication use. Several large-scale, multi-center retrospective and prospective MIGS clinical studies further evaluating the OMNI Surgical System are underway and in their advanced stages.
The OMNI Surgical System combines two distinct angle procedures, ab interno trabeculotomy and transluminal viscoelastic delivery. It is the only MIGS device that allows surgeons to target all three points of aqueous humor outflow resistance: trabecular meshwork, Schlemm's canal and distal collector channels.
"We designed the next generation of our OMNI Surgical System to provide improved ergonomics, intuitive use and smooth microcatheter deployment and retraction, while continuing to deliver excellent outcomes as a standalone treatment, or as a procedure performed in conjunction with cataract surgery," said Sight Sciences Chief Commercial Officer Shawn O'Neil. "We're excited to announce the availability of this improved system, which incorporates many changes based on feedback from our physician customers."
The upgraded system features several updates designed to enhance its ergonomics and usability including:
- An updated Luer lock fitting and pull pin to provide increased efficiency in the priming and preparation of the device,
- An ergonomic handle and flexi-grip surface, which fits comfortably and provides stability in the surgeon's hand, and
- Enhanced gearing and intuitive wheel design that enables seamless deployment and retraction of the microcatheter.
"The OMNI Surgical System has been revolutionary for my practice because of its effectiveness and ability to offer titratable therapy to a wide range of patients with glaucoma," said Blake K. Williamson M.D., MPH, MS, refractive surgeon and MIGS expert at Williamson Eye in Baton Rouge, La. "These changes will improve the functionality and intuitive use of the OMNI System, making it even more comfortable and efficient to perform both viscodilations and trabeculotomies."
Initial published results from early use of the OMNI Surgical System show meaningful reductions in intraocular pressure (IOP) and medication use. Several large-scale, multi-center retrospective and prospective MIGS clinical studies further evaluating the OMNI Surgical System are underway and in their advanced stages.